Tags

Type your tag names separated by a space and hit enter

Efficacy of Multiple Dexamethasone Intravitreal Implants for Refractory Retinal Vein Occlusion-Related Macular Edema and Effect of Prior Vitrectomy.
J Ocul Pharmacol Ther. 2018 12; 34(10):710-719.JO

Abstract

Purpose:

To evaluate the efficacy of dexamethasone intravitreal implants (DEX implant) in patients with treatment-resistant macular edema (ME) owing to branch and central retinal vein occlusion (BRVO/CRVO), and the influence of prior vitrectomy on this treatment.

Methods:

Multicenter retrospective chart review was performed on 40 CRVO and 32 BRVO eyes with persistent ME despite intravitreal anti-vascular endothelial growth factor agents and/or intravitreal triamcinolone, and/or laser therapy. Each patient received ≥1 dexamethasone 700 μg implant between March 2011 and December 2015. Thirteen patients underwent prior vitrectomy. Data were collected on best-corrected visual acuity (BCVA), central macular thickness (CMT), time to relapse, and adverse events.

Results:

At the end of follow-up, BRVO eyes had a lesser CMT reduction from baseline compared to CRVO eyes (-122.50 ± 152.47 μm and -202.26 ± 194.09 μm, respectively). Neither BRVO nor CRVO eyes had a sustained BCVA benefit (P = 0.7041 and P = 0.7027, respectively). Vitrectomized and nonvitrectomized eyes overall had a sustained significant CMT reduction throughout the study with -192.46 ± 172.62 μm and -164.02 ± 180.36 μm, respectively, at final follow-up. Similar time to relapse of 24.4 ± 6.5 and 23.3 ± 13.5 weeks, respectively, was observed. By the end of follow-up, BCVA had only improved in vitrectomized eyes. However, multivariable regression analyses showed no significant association between vitrectomy status and CMT or BCVA change after the first and last injection. Cataract formation and ocular hypertension occurred in 25% and 17%, respectively.

Conclusions:

Multiple DEX implant are effective in reducing CMT in patients resistant to previous treatments and appear to be similarly effective in vitrectomized and nonvitrectomized eyes.

Authors+Show Affiliations

Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium. Faculty of Medicine, Master of Specialist Studies in Medicine: Ophthalmology, Catholic University of Leuven, Leuven, Belgium.Medical Retina and Visual Electrophysiology Division, Department of Ophthalmology, University Hospital Ghent, Gent, Belgium.Vitreoretinal Division, Department of Ophthalmology, East Limburg Hospital, Genk, Belgium. Oogartsen Associatie Maasmechelen, Maasmechelen, Belgium.Department of Ophthalmology, Torbay Hospital, Lowes Bridge, Torquay, Devon, United Kingdom.Oogartsen Associatie Maasmechelen, Maasmechelen, Belgium. Department of Ophthalmology, East Limburg Hospital, Genk, Belgium.Vitreoretinal Division, Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium.

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30403557

Citation

Houben, Isabeau, et al. "Efficacy of Multiple Dexamethasone Intravitreal Implants for Refractory Retinal Vein Occlusion-Related Macular Edema and Effect of Prior Vitrectomy." Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics, vol. 34, no. 10, 2018, pp. 710-719.
Houben I, De Zaeytijd J, Deghislage C, et al. Efficacy of Multiple Dexamethasone Intravitreal Implants for Refractory Retinal Vein Occlusion-Related Macular Edema and Effect of Prior Vitrectomy. J Ocul Pharmacol Ther. 2018;34(10):710-719.
Houben, I., De Zaeytijd, J., Deghislage, C., Frost, N. A., Nijs, I., & Van Calster, J. (2018). Efficacy of Multiple Dexamethasone Intravitreal Implants for Refractory Retinal Vein Occlusion-Related Macular Edema and Effect of Prior Vitrectomy. Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics, 34(10), 710-719. https://doi.org/10.1089/jop.2018.0012
Houben I, et al. Efficacy of Multiple Dexamethasone Intravitreal Implants for Refractory Retinal Vein Occlusion-Related Macular Edema and Effect of Prior Vitrectomy. J Ocul Pharmacol Ther. 2018;34(10):710-719. PubMed PMID: 30403557.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of Multiple Dexamethasone Intravitreal Implants for Refractory Retinal Vein Occlusion-Related Macular Edema and Effect of Prior Vitrectomy. AU - Houben,Isabeau, AU - De Zaeytijd,Julie, AU - Deghislage,Catherine, AU - Frost,N Andrew, AU - Nijs,Ivo, AU - Van Calster,Joachim, Y1 - 2018/11/07/ PY - 2018/11/8/pubmed PY - 2020/6/12/medline PY - 2018/11/8/entrez KW - Ozurdex KW - dexamethasone KW - macular edema KW - retinal vein occlusion KW - treatment-resistant KW - vitrectomy SP - 710 EP - 719 JF - Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics JO - J Ocul Pharmacol Ther VL - 34 IS - 10 N2 - Purpose: To evaluate the efficacy of dexamethasone intravitreal implants (DEX implant) in patients with treatment-resistant macular edema (ME) owing to branch and central retinal vein occlusion (BRVO/CRVO), and the influence of prior vitrectomy on this treatment. Methods: Multicenter retrospective chart review was performed on 40 CRVO and 32 BRVO eyes with persistent ME despite intravitreal anti-vascular endothelial growth factor agents and/or intravitreal triamcinolone, and/or laser therapy. Each patient received ≥1 dexamethasone 700 μg implant between March 2011 and December 2015. Thirteen patients underwent prior vitrectomy. Data were collected on best-corrected visual acuity (BCVA), central macular thickness (CMT), time to relapse, and adverse events. Results: At the end of follow-up, BRVO eyes had a lesser CMT reduction from baseline compared to CRVO eyes (-122.50 ± 152.47 μm and -202.26 ± 194.09 μm, respectively). Neither BRVO nor CRVO eyes had a sustained BCVA benefit (P = 0.7041 and P = 0.7027, respectively). Vitrectomized and nonvitrectomized eyes overall had a sustained significant CMT reduction throughout the study with -192.46 ± 172.62 μm and -164.02 ± 180.36 μm, respectively, at final follow-up. Similar time to relapse of 24.4 ± 6.5 and 23.3 ± 13.5 weeks, respectively, was observed. By the end of follow-up, BCVA had only improved in vitrectomized eyes. However, multivariable regression analyses showed no significant association between vitrectomy status and CMT or BCVA change after the first and last injection. Cataract formation and ocular hypertension occurred in 25% and 17%, respectively. Conclusions: Multiple DEX implant are effective in reducing CMT in patients resistant to previous treatments and appear to be similarly effective in vitrectomized and nonvitrectomized eyes. SN - 1557-7732 UR - https://www.unboundmedicine.com/medline/citation/30403557/Efficacy_of_Multiple_Dexamethasone_Intravitreal_Implants_for_Refractory_Retinal_Vein_Occlusion_Related_Macular_Edema_and_Effect_of_Prior_Vitrectomy_ L2 - https://www.liebertpub.com/doi/10.1089/jop.2018.0012?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -